Mega Lifesciences stock gains as first-half profit climbs 33.1%

Published on 10/31/2026 at 01:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mega Lifesciences stock enters the November 12 results date after stronger first-half revenue and EBITDA. Management also lists a November 13 call.

Profit growth meets execution risks

First-half operating revenue rose 12.5 percent year on year, while EBITDA increased 33.8 percent.
The next earnings announcement is scheduled for November 12, followed by an earnings conference call on November 13.
Analyst commentary highlights capacity expansion, cash conversion and product mix as key issues for the investment case.

Mega, TH0765010002, Illustration mit AI erstellt.

Mega Lifesciences reported a 33.1 percent increase in first-half 2026 net profit, according to the company's investor-relations page. The update covers the six months ended in 2026 and points to stronger operating momentum ahead of the company's next scheduled results.

Revenue and margins move higher

Operating revenue grew 12.5 percent from a year earlier, while EBITDA increased 33.8 percent. Gross profit represented 52.0 percent of operating revenue and selling, general and administrative expenses accounted for 33.0 percent.

The company also distinguishes between reported and adjusted profit. Reported net profit rose 33.1 percent, while adjusted net profit increased 11.7 percent, showing that the headline improvement was stronger than the adjusted measure.

Capacity spending remains central

A Simply Wall St analysis linked the investment debate to manufacturing expansion, product mix and execution of a planned capital-spending program of THB 2.6 billion to THB 2.7 billion. The analysis also identified working-capital demands and cash conversion as factors that could shape how quickly new capacity contributes to earnings.

The same analysis said second-quarter 2026 revenue reached THB 3,547.183 million and net income THB 514.611 million, compared with THB 3,420.070 million and THB 390.918 million a year earlier. Net margin increased to 14.5 percent from 11.4 percent.

What investors should watch next

Mega Lifesciences lists its third-quarter 2026 earnings announcement for November 12, 2026, with the conference call scheduled for November 13. The dates give investors a near-term test of whether revenue growth and margin expansion are continuing beyond the first half.

Investors can follow the Mega Lifesciences stock page for further company developments.

Business model and competition

Mega Lifesciences manufactures and sells health food supplements, prescription medicines, over-the-counter products, herbal products, vitamins and fast-moving consumer goods. Simply Wall St describes three operating segments: Brands, Distribution and Original Equipment Manufacture, with products sold across wellness, nutrition and healthcare categories.

The company is based in Thailand and serves international markets through its health and pharmaceutical portfolio. In the Thai pharmaceuticals market, Simply Wall St names T.Man Pharmaceutical and Bangkok Lab and Cosmetic as competitors; Mega Lifesciences is larger than both in the market-cap figures shown on that page, while remaining focused on branded health products and distribution.